Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Lung Neoplasms 13Pancreatic Neoplasms 5Non-Squamous Non-Small Cell Lung Cancer 5Neoplasms 4Colorectal Neoplasms 3Thoracic Neoplasms 2Respiratory Tract Diseases 2Neoplasm Metastasis 2Carcinoma 2Brain Neoplasms 2Stage IV EGFR Mutated Non-Small Cell Lung Cancer 1Solid Tumor 1Respiratory Tract Neoplasms 1Rectal Neoplasms 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Non-squamous Non-small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neoplasms by Site 1NSCLC 1Mouth Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

valrubicin 1dodecyl maltoside 1Standard of Care 1Physical Examination 1Mitomycin 1Methods 1Mastectomy, Subcutaneous 1Erlotinib Hydrochloride 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma in Situ × Erlotinib Hydrochloride × Clear all
NCT00402779 2020-04-21

Erlotinib Prevention of Oral Cancer (EPOC)

M.D. Anderson Cancer Center

Phase 3 Completed
303 enrolled 11 charts
Head & Neck

Carcinoma in Situ, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡